Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Reimbursement Woes Could Impact Charité Sales – Spine Surgeon Blumenthal

This article was originally published in The Gray Sheet

Executive Summary

Third-party payor reluctance to reimburse for Johnson & Johnson/DePuy's Charité total artificial disc could hinder its adoption, the device's principal investigator, Scott Blumenthal, MD, Texas Back Institute, contends

You may also be interested in...



Financings In Brief

Spinal Motion: Series B financing of $20 mil. will fund enrollment of the firm's SpinalMotion Kineflex lumbar disc and SpinalMotion Kineflex-C cervical disc U.S. clinical trials, President & CEO David Hovda says. The lumbar disc study, to take place at 25 centers, will seek to prove SpinalMotion Kineflex is substantially equivalent to Johnson & Johnson/DePuy's Charité - currently the only FDA-approved artificial spine disc (1"The Gray Sheet" Jan. 17, 2005, p. 15). The cervical disc trial will involve 20 sites and compare the Spinal Motion product to spinal fusion. Three Arch Partners and Thomas Weisel Healthcare Venture Partners participated in the funding round...

Financings In Brief

Spinal Motion: Series B financing of $20 mil. will fund enrollment of the firm's SpinalMotion Kineflex lumbar disc and SpinalMotion Kineflex-C cervical disc U.S. clinical trials, President & CEO David Hovda says. The lumbar disc study, to take place at 25 centers, will seek to prove SpinalMotion Kineflex is substantially equivalent to Johnson & Johnson/DePuy's Charité - currently the only FDA-approved artificial spine disc (1"The Gray Sheet" Jan. 17, 2005, p. 15). The cervical disc trial will involve 20 sites and compare the Spinal Motion product to spinal fusion. Three Arch Partners and Thomas Weisel Healthcare Venture Partners participated in the funding round...

Is CMS Charitably Inclined Toward DePuy Spine Disc? Other Payors Take Heed

Johnson & Johnson/DePuy will submit hospital claims data to CMS in an effort to convince the agency that the Charité artificial spine disc yields better outcomes for Medicare patients when compared with fusion

Related Content

Latest Headlines
See All
UsernamePublicRestriction

Register

MT021467

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel